Inventor · disambiguated record
Fude Huang
Also filed as: HUANG FUDE
2 granted patents·7 pending applications·1 citations·filing 2015–2023
34Inventor score
Files withJIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD4NUO BETA PHARMACEUTICAL TECH SHANGHAI CO LTD4NUO BETA PHARMACEUTICAL TECH SHANGHAIA CO LTD1
Top patents by PatentIndex Score
9 records- 0168US11766420B2Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's diseaseJIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD·Filed 2016·Granted Sep 26, 2023·1 cites·5 claims
- 0264US2024173287A1Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's DiseaseJIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD·Filed 2023·Application pending·0 cites
- 0353US2024050395A1Deuterated oxophenylarsine compound and use thereofNUO BETA PHARMACEUTICAL TECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0453US2024391942A1Halogenated phenylarsine oxide compound and application thereofNUO BETA PHARMACEUTICAL TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0549US2024261250A1Applications of p14k inhibitor in intracellular protein misfolding-related diseases and lysosomal storage diseasesNUO BETA PHARMACEUTICAL TECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0644US2023115711A1MICROMOLECULE PI4KIIIalpha INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOFNUO BETA PHARMACEUTICAL TECH SHANGHAIA CO LTD·Filed 2020·Application pending·0 cites
- 0743US11236378B2Method for screening drug and therapeutic targets used for treating Alzheimer's diseaseJIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD·Filed 2015·Granted Feb 1, 2022·0 cites·7 claims
- 0842US2025152599A1Anti-coronavirus effect and application of p14k inhibitorNUO BETA PHARMACEUTICAL TECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0935US2022362203A1Method for treating mood disordersJIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →